Tafluprost

CAS No. 209860-87-7

Tafluprost( AFP-168,MK2452 )

Catalog No. M22166 CAS No. 209860-87-7

Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 83 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 70 In Stock
25MG 129 In Stock
50MG 184 In Stock
100MG 276 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tafluprost
  • Note
    Research use only, not for human use.
  • Brief Description
    Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
  • Description
    Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma.
  • In Vitro
    Cell Viability Assay Cell Line:RGC Concentration:0.1, 1, 3, 10, 100 μM Incubation Time:48 h Result:Enhanced the viability of these cells in a dose-dependent fashion, with an optimal concentration of 3μM.Increased the relative fluorescence intensity (RFI).
  • In Vivo
    Animal Model:Male Sprague rat model Dosage:0.0015% Administration:Via eye drops Result:Increased the number of RGCs and reduced the number of TUNEL-positive cells.Animal Model:Prostaglandin receptor deletion C57BL/6 mice model Dosage:3 μL (0.0015% Tafluprost)Administration:Instillation; Single dose Result:Reduced IOP in WT, EP1KO, EP2KO, EP3KO and FPKO mice, and the average IOP reduction rates were 25.8(2.1)%, 26.3(0.8)%, 24.2(1.4)%, 16.5(1.7)% and 20.9(1.5)%, respectively. (The decrease of IOP in EP3KO and FPKO mice was less than that in WT mice.)
  • Synonyms
    AFP-168,MK2452
  • Pathway
    GPCR/G Protein
  • Target
    Prostaglandin Receptor
  • Recptor
    PGF2α
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    209860-87-7
  • Formula Weight
    452.53
  • Molecular Formula
    C25H34F2O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (552.45 mM)
  • SMILES
    CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.
molnova catalog
related products
  • Terbogrel

    Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM).

  • EP4 receptor antagon...

    EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively.

  • BGC20-1531

    BGC20-1531 (PGN-1531, AP 1531) is a potent, selective prostanoid EP receptor EP antagonist.